Back to Journals » Biologics: Targets and Therapy » Volume 7 » default

Biologics: Targets and Therapy


Archived Journals

Archive: Volume 7, 2013

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M

Biologics: Targets and Therapy 2013, 7:265-266

Published Date: 6 December 2013

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

Mathieu S, Couderc M, Glace B, Pereira B, Tournadre A, Dubost JJ, Soubrier M

Biologics: Targets and Therapy 2013, 7:259-264

Published Date: 2 December 2013

Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus

Ideno S, Sakai K, Yunoki M, Kubota-Koketsu R, Inoue Y, Nakamura S, Yasunaga T, Okuno Y, Ikuta K

Biologics: Targets and Therapy 2013, 7:233-241

Published Date: 5 November 2013

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:231-232

Published Date: 31 October 2013

Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck

Yang H, Diao LQ, Shi M, Ma R, Wang JH, Li JP, Xiao F, Xue Y, Xu M, Zhou B

Biologics: Targets and Therapy 2013, 7:223-229

Published Date: 18 October 2013

Clinical utility of asthma biomarkers: from bench to bedside

Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Biologics: Targets and Therapy 2013, 7:199-210

Published Date: 29 August 2013

Treatment and management of myelofibrosis in the era of JAK inhibitors

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:189-198

Published Date: 20 August 2013

Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus

Pipattanaboon C, Sasaki T, Nishimura M, Setthapramote C, Pitaksajjakul P, Leaungwutiwong P, Limkittikul K, Puiprom O, Sasayama M, Chaichana P, Okabayashi T, Kurosu T, Ono K, Ramasoota P, Ikuta K

Biologics: Targets and Therapy 2013, 7:175-187

Published Date: 15 August 2013

Tivozanib in the treatment of renal cell carcinoma

Hepgur M, Sadeghi S, Dorff TB, Quinn DI

Biologics: Targets and Therapy 2013, 7:139-148

Published Date: 11 June 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013

Cetuximab: its unique place in head and neck cancer treatment

Specenier P, Vermorken JB

Biologics: Targets and Therapy 2013, 7:77-90

Published Date: 15 April 2013

Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F

Biologics: Targets and Therapy 2013, 7:69-75

Published Date: 15 March 2013

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Ververis K, Hiong A, Karagiannis TC, Licciardi PV

Biologics: Targets and Therapy 2013, 7:47-60

Published Date: 25 February 2013

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ansari J, Hussain SA, Ansari A, Glaholm J

Biologics: Targets and Therapy 2013, 7:39-46

Published Date: 28 February 2013

Treatment of hemophilia B: focus on recombinant factor IX

Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C

Biologics: Targets and Therapy 2013, 7:33-38

Published Date: 12 February 2013

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Nooka A, Gleason C, Casbourne D, Lonial S

Biologics: Targets and Therapy 2013, 7:13-32

Published Date: 30 January 2013